Roche Holding Ltd · SIX:RO
Roche — Octavian 27th Seminar 2023
22 slides from Roche's conference presentation, Jan 12, 2023
Slide 1: Roche
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Growing through Innovation
Growing through Innovation Severin Schwan | CEO Roche Octavian Conference, 12 January 2023
Slide 4: Pharma rejuvenation & positioning, Diagnostics upcoming opportunities, Outlook
Pharma rejuvenation & positioning Diagnostics upcoming opportunities Outlook
Slide 5: Broadest set of technology platforms available
Broadest set of technology platforms available Roche being a pioneer in antibodies, ADCs and bi-specifics List of pipeline molecules shown below is not complete; 1 Repare Therapeutics managed, 2 Poseida Therapeutics managed, 3 Kiniksa Pharmaceuticals managed, 4 Lineage Cell Therapeutics managed, 5IO
Slide 6: BD focus on pipeline acceleration, Diagnostics and digital innovation
BD focus on pipeline acceleration, Diagnostics and digital innovation Development stage at time of deal/partnership start Pharma pipeline: Early stage assets Late stage assets Diagnostics, PHC & digital innovation (NLRP3 inhibitors) (HBV) (molecular information) (electronic health records) (SRP-9001
Slide 7: Pharma portfolio rejuvenation on-going
Pharma portfolio rejuvenation on-going Medicines launched since the end of 2015 account for 42% of sales * CHFm % of Pharma sales 16,000 42% 14,000 34% 12,000 10,000 23% 8,000 15% 6,000 4,000 2,000 0 YTD Sep 2019 YTD Sep 2020 YTD Sep 2021 YTD Sep 2022 Cotellic Alecensa Tecentriq Ocrevus Hemlibra Xof
Slide 8: Evolving as leader in Ophthalmology, Neuroscience, Hematology
Evolving as leader in Ophthalmology, Neuroscience, Hematology YTD Sep 2022 Pharma sales Record number of NMEs and AIs (YTD Sep 2022) YTD Sep 2017 YTD Sep 2022 Phase I Phase II CHF 30.6bn CHF 33.2bn 2% 3% 8% 10% 4% 3% 3% 3% 11% 9% 7% 15% 38% 3% 3% 9% 62 29 11% 31% 65% 14% 52% 17% 31% 6% 10% 15% 15% P
Slide 9: Ophthalmology: Set to become a market leader
Ophthalmology: Set to become a market leader HC systems recognize importance of durability to overall outcomes and costs Initial uptake in high unmet need patients Global retina market growing to USD 15 bn1 • Strong customer uptake with switching coming primarily from aflibercept • Uptake across bot
Slide 10: Hematology market expected to grow substantially
Hematology market expected to grow substantially Roche has one of the broadest hematology portfolios with ~20 agents in 10+ diseases Global hematology market Roche’s hematology portfolio is well positioned in a growing market growing to USD 109bn1 109 † glofitamab (CD20 x CD3), 18 DLBCL CD19 x 4-1BB
Slide 11: Tiragolumab development program with read-outs in 2023
Tiragolumab development program with read-outs in 2023 Early data (SKYSCRAPER-01) show encouraging efficiency in 1L PDL1+ NSCLC Anti-TIGIT mAb Tiragolumab development program • Fully human IgG1/kappa Ab with intact Fc • SKYSCRAPER-01 did not meet its co-primary PFS endpoint. The co-primary OS endpoi
Slide 12: Key late-stage pipeline readouts 2023
Key late-stage pipeline readouts 2023 * Compound Indication Data readout Tecentriq + chemo Neoadjuvant / adjuvant NSCLC Ph III IMpower030 Tecentriq + Avastin Adjuvant HCC Ph III IMbrave050 Tecentriq + chemo Neoadjuvant / adjuvant TNBC Ph III GeparDouze/NSABP B-59 Tecentriq Adjuvant SCCHN Ph III IMvo
Slide 13: Pharma rejuvenation & positioning, Diagnostics upcoming opportunities, Outlook
Pharma rejuvenation & positioning Diagnostics upcoming opportunities Outlook
Slide 14: High throughput testing solution driving Diagnostics base business
High throughput testing solution driving Diagnostics base business Diagnostics Installed base for cobas 6800/8800 Quarterly sales evolution 2021-2022 Sales evolution 2018- Q3 2022 % CER +55% +48% +55% +45% +35% +31% +24% +25% +17% +18% +15% +9% +7% +5% +11% +10% +3% +8% -5% 0% -4% -15% Q1 Q2 Q3 Q4 Q
Slide 15: Serum Work Area (SWA) menu expansion driving future growth
Serum Work Area (SWA) menu expansion driving future growth >240 assays running on >100k installed cobas® SWA instruments Broad IM + CC assay menu Launched in 2021 & 2022 Immuno chemistry assays Clinical chemistry assays EBV EBNA IgG (CE) IGRA SARS-CoV-2 (CE) Fentanyl3 (CE, US) Benz 22 (US) EBV VCA I
Slide 16: Elecsys Amyloid Plasma Panel clinical results
Elecsys® Amyloid Plasma Panel clinical results Addressing the unmet need of early detection of Alzheimer’s disease pathology 1 2 3 Triage Confirmation Therapy Patients undergoing initial evaluation Patients referred for amyloid Patients identified for future therapies for non-specific cognitive decl
Slide 17: Pharma rejuvenation & positioning, Diagnostics upcoming opportunities, Outlook
Pharma rejuvenation & positioning Diagnostics upcoming opportunities Outlook
Slide 18: YTD Sep 2022: Solid underlying sales growth in both divisions
YTD Sep 2022: Solid underlying sales growth in both divisions Pharma Diagnostics Quarterly sales evolution 2021-2022 Quarterly sales evolution 2021-2022 % CER % CER +55% +55% +48% +45% +55% +45% +35% +35% +31% +24% +25% +25% +17% +18% +15% +14% +15% +9% +7% +4% +5% +6% +6% +3% +5% +2% +5% +11% +10%
Slide 19: Reallocating resources while securing margins and cash flow
Reallocating resources while securing margins and cash flow Operating expenses (OPEX) and Core OP 2018 - 2021 Operating free cash flow % of total OPEX CHFbn 70% 14.0 60% 12.0 53% 50% 50% 47% 47% 10.0 R&D spend 40% 8.0 R&D 42% 42% 39% 37% M&D 30% 6.0 G&A 20% 4.0 10% 2.0 11% 11% 11% 10% 0% 0.0 2018 20
Slide 20: 2021: 35th consecutive annual dividend increase
2021: 35th consecutive annual dividend increase CHF 10 9.30 9 8 7 6 5 4 3 2 1 0 1989 1994 1999 2004 2009 2014 2019 2021 dividend as proposed by the Board of Directors; Note: For 1995, a special dividend was paid out to mark F. Hoffmann-La Roche’s 100th anniversary in 1996 20
Slide 21: 2022 outlook confirmed
2022 outlook confirmed Group sales growth1 • Stable to low-single digit Core EPS growth1 • Low- to mid-single digit Dividend outlook • Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER) 21
Slide 22: Doing now what patients need next
Doing now what patients need next 22